Shares of Finch Therapeutics Group, Inc. (NASDAQ:FNCH – Get Free Report) were up 1.3% on Monday . The company traded as high as $11.94 and last traded at $11.65. Approximately 2,841 shares traded hands during mid-day trading, a decline of 91% from the average daily volume of 30,110 shares. The stock had previously closed at $11.50.
Finch Therapeutics Group Price Performance
The firm has a 50-day simple moving average of $11.44 and a 200-day simple moving average of $5.20. The firm has a market capitalization of $19.35 million, a PE ratio of -1.19 and a beta of 1.34.
Finch Therapeutics Group (NASDAQ:FNCH – Get Free Report) last announced its earnings results on Tuesday, August 13th. The company reported ($3.01) earnings per share (EPS) for the quarter.
Hedge Funds Weigh In On Finch Therapeutics Group
About Finch Therapeutics Group
Finch Therapeutics Group, Inc, a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates.
Further Reading
- Five stocks we like better than Finch Therapeutics Group
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- Taiwan Semiconductor Stock: Buy Now or Wait for Earnings?
- How to Calculate Return on Investment (ROI)
- Abbott’s Growth and Dividends Make It a Smart Portfolio Pick
- What is a SEC Filing?
- Citigroup Faces Growing Troubles: Could the Industry Be at Risk?
Receive News & Ratings for Finch Therapeutics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Finch Therapeutics Group and related companies with MarketBeat.com's FREE daily email newsletter.